Viable human embryos carrying a disease mutation have now been corrected by CRISPR-Cas9 editing. Although the correction is not perfect, and the embryos have not been implanted, this brings us closer to human germline ...

Since the completion of the first human DNA sequence, genomic approaches have penetrated into cancer research and therapy: first through expression profiling for diagnostic, prognostic and predictive purposes, then by ...

In clinical oncology, obtaining sequence data from tumour samples has become practical in terms of logistics, turnover time and costs. The major issue now is the interpretation of this sequence to define actionable targets, ...

The announcement of several deals between the DTC genetics firm 23andMe and Genentech, Pfizer and other corporations reveals the real business model of the company: selling access to sets of characterized patients for ...

Alternative bases that can fit into the DNA double helix have now been used in vivo to direct the synthesis of proteins incorporating unnatural amino acids. This bioengineering feat is significant at both the conceptual ...

Recent efforts at gene therapy for haemophilia A and B using AAV-derived vectors show durable expression of coagulation factors at significant levels, resulting in almost complete correction of the phenotype. This is the ...

Senescent cells are involved in many age-related diseases, and the effects of their elimination by “senolytic” drugs is an active research field. A recent paper describes a convenient murine model of induced senescence and ...

Analysis of a huge human pedigree constructed using public genealogy databases indicates that the heritability of longevity is probably lower than previously accepted (0.10 to 0.15 instead of 0.25 to 0.30). This makes the ...

Comme on l’a dit et répété dans ces colonnes [1–3], la valeur prédictive des profils génétiques à base de Snip vendus par 23andMe, Navigenics et autres « entreprises DTC » (direct to consumer) est très faible pour ne pas ...